Halted trial tests hopeful drug combo for Tough-to-Treat cancer
NCT ID NCT04203160
Summary
This study tested whether adding an experimental drug called CPI-613 to standard chemotherapy could better control advanced bile duct cancer. It involved 75 adults with cancer that couldn't be removed by surgery and who hadn't had prior treatment for advanced disease. The trial was designed to first find a safe dose, then compare the new combination against standard chemo alone, but it was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15224, United States
-
Atlantic Health System
Morristown, New Jersey, 07960, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Northwestern University -- Lurie Comprehensive Cancer Center
Chicago, Illinois, 60611, United States
-
University Hospitals - Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
University of Arizona Cancer Center
Tucson, Arizona, 85724, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Texas Southwestern -- Simmons Comprehensive Cancer Center
Dallas, Texas, 75390, United States
-
University of Wisconsin - Carbone Cancer Center
Madison, Wisconsin, 53705, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.